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SUMMARY 
Consumption of natural products with high nutritional value can improve nutritional and immune status of HIV 
patients. Arthrospira  platensis, is an alga that grows naturally in some tropical lakes. It is rich in nutritional 
contents and antioxidants. This study investigated whether use of Arthrospira platensis by HIV positive adults 
affected their CD4+ Tcell counts. This was a prospective paired study design with two independent groups: 
the study group and a control group. The findings of individual patients before and after intervention were also 
paired. Patients with CD4+ Tcell counts above 250 cells/1l were enrolled in Nyanza Provincial Hospital, Kenya. 
Patients in the study group used A. platensis while those in the control group used the standard multivitamin 
supplements. Fiftyeight patients completed the study [28 in A. platensis (study) group and 30 in multivitamin 
(control) group]. The mean CD4+ Tcell counts among patients in the study group increased from 485 ± 163 
to 516 ± 181 cells/1l (p = 0.110) while in the multivitamin group they declined from 555 ± 221 to 472 ± 174 
cells/1l (p = 0.001). It was concluded that A. platensis increased CD4+ Tcell counts in HIV infected adults and 
it was well tolerated at a maximum dry dose of 2g/day when used for 16 months. 
[Afr J Health Sci. 2013; 24:18] 
Introduction 
Highly active antiretroviral therapy (HAART) has had 
remarkable success in the management of HIV 
infection, though it is difficult to eradicate the infection. 
The latent form serves as a permanent archive for wild 
type virus and for drug resistant variants that may arise 
during treatment [1]. Treatment using HAART aims at 
reducing the replication of HIV, thus allowing the 
immune system to recover. 
A recent study has shown that most HIV patients on 
HAART do not infect their sexual partners [2]. These 
findings led the researchers to recommend early 
initiation of HIV treatment in order to prevent the spread 
of the infection.  
Before immunosuppression occurs, the aim of 
management has been to maintain the intact immunity 
for as long as possible by prevention and treatment of 
opportunistic infections, together with nutritional 
counseling and supplementation. Currently in Kenya, an 
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antibiotic (commonly Cotrimoxazole) and multi
vitamins are used for these purposes respectively [3,4]. 
Supplementation with multivitamins or consumption of 
products with a high nutritional value has been shown 
to be beneficial to HIV infected patients [5, 6].   
A. platensis contains essential amino acids including 
the four basic components of the selenoenzyme 
glutathione peroxidase, namely selenium, cysteine, 
glutamine, and tryptophan. It is also rich in 
phytonutrients, essential fatty acids (EFA’s) [7] and C
phycocyanin (a biliprotein) that has antioxidant and 
radical scavenging activities, among other components 
[8]. 
Many toxicological studies have proven Arthrospira 
platensis’s safety [9] and it is used as a food 
supplement especially in parts of Mexico, Central Africa, 
Congo and India [10]. It has been used among the 
undernourished children, both HIV positive and negative 
without serious undesirable effects reported [11].  
The effect of Arthrospira platensis on CD4+ Tcell 
levels in HIV patients monitored over a period of time 
was, however, not clear. One study in Yaoundé 
Cameroon among HIV positive pregnant women was 
done recently [12], but using a different dose and, 
probably, form, and the outcome had not been 
published as this one was ongoing. The current study 
sought to monitor CD4+ Tcell levels in HIV patients 
using a specified dose and form of this supplement 
over a specified period. It was hoped that a clearer 
effect of this algae in HIV patients from the results of 
these studies with would emerge. 
 
Materials and Methods 
The study was carriedout between October 2009 and 
June 2010 at patient support centre (PSC) clinic in 
Nyanza provincial hospital in Kisumu, and the 
laboratory tests were done at KEMRI/CDC within the 
Hospital compound. Approval was sought and obtained 
from KEMRI scientific and ethical committees and the 
hospital ethics review committee before commencing 
the study. 
The ponds for the growth of the algae were constructed 
at Kenya medical research Institute, Kisumu. The initial 
culture of Arthrospira platensis  algae was obtained 
from a nongovernmental organization running feeding 
programs that involved adding fresh algae to food 
(usually porridge), and used by the malnourished 
children and adults. The culture was then put in a pre
constructed ponds containing water with the required 
nutrients needed for optimal growth (close to 
composition of Farouk’s medium, used in some 
bacterial cultures). 
After growing for at least 4 weeks, the culture was then 
sieved, filtered and dried. Dried Arthrospira platensis 
was made to powder using a blender and then put into 
size “O” capsules, using a manual capsule filler, each 
holding 500 mg of the powder. These were then 
packaged in plastic sealable polythene sachets to 
contain 112 capsules to be taken for 28 days, two 
capsules taken twice daily with meals (a total of 
2g/day). This dose was based on preliminary findings 
that indicated that this was an effective dose that raised 
CD4+ Tcell levels without eliciting major adverse 
events.  
Consenting HIV positive adult outpatients with CD4+ 
Tcell counts above 250 cells/Ll (the counts used at 
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the hospital as cutoff for initiation of ARV therapy) and 
not on ARV’s were enrolled. Patients were assigned 
into one of the two groups, the study group who used 
A. platensis or a control group who used multivitamins.  
Blood samples from each patient were analyzed at 
enrolment and during clinic visits, often monthly or after 
three months. The sample obtained before intervention 
also served as control and paired with sample/s 
obtained after the intervention. Each subject therefore 
also served as his/her own control, which allowed 
change to be detected more easily by controlling for 
extraneous variation among the observations. Many 
biological measurements exhibit wide variation among 
individuals, and the use of paired design was thus 
especially appropriate. 
The formula used to calculate the sample size was n = 
2 ×[(Zα  Zβ)
 2 /(∆) 2  [13]. 
Specifications of level of significance (α) for null 
hypothesis and the desired level of power (β) for an 
alternative hypothesis permit us to solve for sample 
size. α, is type I error where a conclusion is drawn that 
there is a rise in CD4+ Tcell counts after using the 
supplement while there is not. The desired level of 
significance used was 0.05, it’s z value is 1.96, and 
the desired level of power of 80% whose lower one 
tailed z value related to β is 0.84.  
Based on preliminary results, the mean CD4+ Tcell 
counts of 520 ± 173 cells/µl at the beginning of the 
study was used. An estimated change of 12.5% at the 
end of the study was assumed. The assumption was 
that CD4+ counts among patients in the standard 
multivitamin (control) group would decline by 12.5% to 
455 [520 12.5% of 520 (= 65)], while those in the 
study group would rise by a similar margin of 12.5% to 
585 (520+65). 
∆ is the Standardized difference of the means of the 
two groups, obtained from (585455)/ 173 (s.d) = 
0.751 
Using the indicated formula, at least 28 participants per 
group were required, or a total of 56 participants.  
All patients followed the routine procedures at the clinic, 
and enrolment to participate in the study was voluntary 
but involved meeting specified criteria. Consenting 
adults with CD4+ Tcell counts above 250 cells/Ll were 
enrolled. The recruited patients were issued with the 
supplements, either multivitamin tablets (control group) 
or A. platensis capsules (study group).  
All HIV patients were also put on cotrimoxazole 
prophylaxis since this was the recommended 
prophylactic antibiotic for HIV infected patients.  
After every 4 weeks (most patients) or 12 weeks (some 
patients in the control group), patients came to 
replenish their supplies and also to evaluate their 
clinical state, asses their treatment adherence and 
perform scheduled laboratory investigations. The clinical 
and laboratory monitoring done during these visits were 
aimed at early detection of opportunistic infections or 
occurrence of adverse events. Patients found to have 
any other disease or infection received appropriate 
prescription to obtain drugs at the hospital pharmacy.  
The information obtained was analyzed in SPSS 
program and Ttest performed, which is suitable for 
paired samples.   
Results 
Eightyone patients were enrolled, 58 females (71.2%) 
and 23 males (28.8%). 58 patients (71.6%) completed 
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the study, of which, 43 were females and 15 were 
males. This showed the male: female ratio of about 
1:3. The results are as summarized in table 1. 
Table 1: Number of patients enrolled and their 
completion rate  
The mean age for all the patients was 27.4 ± 5.7 
years, with that of  males being 30.5 ± 7.2 years and 
that of females  26.4 ± 4.7 years. More than 75% of all 
the patients enrolled were 30 years old and below. 
At the end of the study, the total lymphocyte counts 
among patients in the study group remained stable, 
being 1.92 ± 0.75 × 103 cells/µl at the beginning of the 
study and 1.92 ± 0.47 × 103 cells/µl (p= 0.994) at the 
end of the study. The counts among those in the 
control group declined from 2.33 ± 0.90 × 103 cells/µl 
to 2.06 ± 0.90 × 103 cells/µl, which was significant (p= 
0.002).    
At the beginning of the study, the mean CD4+ Tcell 
counts among the patients in the study group was 485 
± 163 cells/Ll, rising to 516 ± 181 cells/Ll at the end of 
the study (table 2). This change was not statistically 
significant (p= 0.110). The mean CD4+ Tcell counts 
among the patients on multivitamin (control group)  
was 555 ±  221 cells/Ll at the beginning of the study 
declining to 472 ± 174 cells/Ll at the end of the study. 
This decline was statistically significant (p= 0.002).   




Study group Control group 
At beginning 
of study 
At end of 
study  
pvalue At beginning of 
study 




counts, ×103 cells /µl 
(1.504.00) 
1.92 1.92 0.994 2.33 2.06 0.002 
CD4+ Tcells count 
(4101590 cells /µl) 
485 516 0.110 555 472 0.002 
CD8+ Tcells count 
(1901140 cells /µl) 
942 899 0.533 1122 982 0.021 
 
Discussion 
In this study, among the 81 enrolled patients, 11 
(13.5%), were lost to followup over a period of six 
months. This is comparable with a previous large study 
among patients initiated on ARV treatment, which 
showed that 16% of the patients were lost to followup 
over six months [14]. 
Among the patients who did not complete the study, 11 
(47.8%) failed to return to the clinic on the date of 
appointment. The other patients, 12 (52.2%), were 




Males 15 8 23 65.2% 
Females 43 15 58 74.1% 
Total 58 23 81 71.6% 
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excluded because of other different reasons. A higher 
proportion of the females (74.1%) completed the study 
as compared to the males (65.2%). The reasons for 
these difference was not clear.   
A male: female ratio of about 1:3 was a general 
reflection of the HIV clinic attendance. 
The average age for all patients in the current study 
was 27.4 years. An earlier study on HIV patients before 
initiation of antiretroviral treatment showed that the 
average age for the patients was 38 years [15]. That 
study was done about five years earlier than the current 
one. The possible explanations to this apparent 10
year difference in the average ages could be because 
HIV infection is now occurring in younger population.  
Another observation was that the females tended to be 
younger than the males, where the average age of the 
females in this study was 26.4 years while that of the 
males was 30.5 years.  
HIV infection, in most patients, ultimately leads to 
depletion of CD4+ Tcells. It is not uncommon for CD4+ 
T cell counts to drop as low as 10 cells/µl or even 0, 
yet the patients may survive for months or even for 
more than 1 year [16]. The situation has become 
increasingly common as patients are treated more 
aggressively including treatment of opportunistic 
diseases or are given prophylactic treatment against 
them. Ultimately, without proper treatment, patients who 
progress to this severest form of immunosuppression 
usually succumb to opportunistic infections or 
neoplasms. 
There have been reports that an abnormally high 
percentage of CD8+CD38+ Tcells predict decline of 
CD4+ Tcells and the rate of disease 
progression in HIV1 infected adults [17, 18] and 
pediatric patients [19].  The biological basis for the 
negative prognostic value of CD8+CD38+ Tcells is 
unknown. In the current study, patients with high CD8+ 
Tcells predicted a decline of CD4+Tcells. It could not, 
however, be established whether these were 
CD8+CD38+ Tcells as this was a later finding during 
analysis of the results and  tests to estimate the counts 
of CD8+CD38+ Tcells had not been included in the 
protocol.   
The dosage of A. platensis used in this study was 
based on the available information. In Kisumu town, the 
area of the current study, A. platensis was being used 
as food supplement for malnutrition by some adults and 
children, where 10g of fresh A. platensis, obtained after 
draining away the growth medium by sieving and 
filtering, was used. This amount was added to a cup of 
sugarless porridge for adults and 5g for children, and 
then drank once in the morning. Alternatively, 5g of 
dried and powdered A. platensis was given to adults to 
be used at home daily for the same purpose [IMSAM, 
Unpublished report].  
A study on healthy human subjects also indicated that 
using 4.2 g/day of Arthrospira platensis was safe [10]. 
To test a hypothesis that there is no difference in CD4+ 
Tcell counts before and after using the supplements, 
Ttest was used. In the A. platensis group, the 
statistical analysis of the CD4+ Tcell counts before and 
after using this supplement was that, from a statistical 
table, with an area of 0.05 in two tails and with the 
degrees of freedom (df) 27, the critical value for the t 
distribution is 2.05 (or 2.05), obtained from a ttable. 
An α value of 0.110 was obtained in the study group, 
which is >0.05. Using SPSS to find the tvalue in the 
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study group, a t value of 1.652 was obtained, which 
lies in the range between 2.05 and +2.05 and 
therefore we accept the null hypothesis that there is no 
difference between CD4+ Tcell counts before and after 
using A. platensis and reject the alternative hypothesis 
that there is a difference.  
In the multivitamin group, the statistical analysis of the 
CD4+ Tcell counts before and after using this 
supplement was that α value of 0.002 was obtained, 
which is much less than 0.05, and a df of 29. The 
obtained t value of +3.437 lies outside the interval 
2.05 and +2.05 and therefore we reject the null 
hypothesis that there is no difference between CD4 
counts before and after using the supplement and 
accept the alternative hypothesis that there is a 
difference. 
Conclusions   
In conclusion, these results showed that there was a 
nonsignificant increase in CD4 Tcell counts among 
HIV infected adults taking Arthrospira platensis (study 
group) supplement after using for a period of one to six 
months. There was also a significant decrease in CD4 
Tcell counts among HIV infected adults taking multi
vitamins (control group). Arthrospira platensis was also 
well tolerated by HIV infected adults at the dose of 2 
g/day for upto six months.  
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